Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Orphan drugs Stories

2013-09-09 08:27:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Sept. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-08-25 20:20:20

Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx...

2013-08-19 15:03:25

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer. "There has been a great deal of debate...

2013-08-13 16:26:07

- Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO, Aug. 13, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial...

2013-07-31 16:27:54

SUNNYVALE, Calif., July 31, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its quarter ended June 30, 2013. Financial Results for the Three and Six Months Ended June 30, 2013 Non-GAAP net income reported for the quarter ended June 30, 2013 was $19.2 million, or $0.26 and $0.25 net income per basic and diluted share, respectively, compared to non-GAAP net loss of $15.1 million, or $0.22 net loss...

2013-07-02 08:26:31

BOULDER, Colo., July 2, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer (LGSOC). (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), is a multinational, randomized Phase 3 trial and will evaluate MEK162 against physician's choice of...

2013-06-18 08:31:20

First Patients Dosed in Multicenter, Randomized, Placebo-Controlled Study SAN DIEGO, June 18, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patients have been dosed in a Phase II clinical trial of its lead drug candidate Pracinostat in combination with Vidaza (azacitidine) in patients with previously untreated intermediate-2 or high-risk myelodysplastic...

2013-06-17 08:28:07

BOULDER, Colo., June 17, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in Stockholm, Sweden. Also at the meeting, Array presented updated information on a potential patient selection marker for ARRY-520. ARRY-520 is a highly selective, targeted inhibitor of KSP with a mechanism of action distinct...

2013-06-11 04:22:15

SEATTLE, June 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentation of data highlighting PIXUVRI(®) (pixantrone), the first approved treatment in the European Union for aggressive B-cell non-Hodgkin lymphoma (NHL) for adult patients who have failed 2 to 3 prior lines of therapy, and results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, a novel, oral JAK2/FLT3 inhibitor, at the 18(th)...

2013-06-05 08:28:09

Targeted Alpha Therapy gains traction with three ongoing clinical alpha trials to be presented at the TAT Symposium in Oak Ridge, TN June 4 - 6, 2013 NEW YORK, June 5, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced the timing for a presentation devoted to its Acute Myeloid Leukemia clinical programs. The presentation is formally...